Exosomes in the Treatment of Pancreatic Cancer: A Moonshot to PDAC Treatment?

Papadakos, Stavros P.; Dedes, Nikolaos; Pergaris, Alexandros; Gazouli, Maria; Theocharis, Stamatios

doi:10.3390/ijms23073620

Open AccessReview

Exosomes in the Treatment of Pancreatic Cancer: A Moonshot to PDAC Treatment?

by

Stavros P. Papadakos

^1,†

,

Nikolaos Dedes

^1,†,

Alexandros Pergaris

¹

,

Maria Gazouli

²

and

Stamatios Theocharis

^1,*

¹

First Department of Pathology, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece

²

Laboratory of Biology, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece

^*

Author to whom correspondence should be addressed.

^†

These authors contributed equally to this work.

Int. J. Mol. Sci. 2022, 23(7), 3620; https://doi.org/10.3390/ijms23073620

Submission received: 27 February 2022 / Revised: 19 March 2022 / Accepted: 23 March 2022 / Published: 25 March 2022

(This article belongs to the Special Issue Molecular Advances in Cancer Therapy)

Download

Browse Figures

Versions Notes

Abstract

Pancreatic Ductal Adenocarcinoma (PDAC) constitutes a leading cause of cancer death globally. Its mortality remains unaltered despite the considerable scientific progress made in the fields of diagnostics and treatment. Exosomes comprise of small extracellular vesicles secreted by nearly all cells; their cargo contains a vast array of biomolecules, such as proteins and microRNAs. It is currently established that their role as messengers is central to a plethora of both physiologic and pathologic processes. Accumulating data have shed light on their contributions to carcinogenesis, metastasis, and immunological response. Meanwhile, the advancement of personalized targeted therapies into everyday clinical practice necessitates the development of cost-efficient treatment approaches. The role of exosomes is currently being extensively investigated towards this direction. This review aims to summarize the current pre-clinical and clinical evidence regarding the effects of exosomal applications in the timely diagnosis, prognosis, and therapeutic management of pancreatic cancer.

Keywords: pancreatic cancer; exosomes; biomarkers; diagnosis; prognosis; therapy

Share and Cite

MDPI and ACS Style

Papadakos, S.P.; Dedes, N.; Pergaris, A.; Gazouli, M.; Theocharis, S. Exosomes in the Treatment of Pancreatic Cancer: A Moonshot to PDAC Treatment? Int. J. Mol. Sci. 2022, 23, 3620. https://doi.org/10.3390/ijms23073620

AMA Style

Papadakos SP, Dedes N, Pergaris A, Gazouli M, Theocharis S. Exosomes in the Treatment of Pancreatic Cancer: A Moonshot to PDAC Treatment? International Journal of Molecular Sciences. 2022; 23(7):3620. https://doi.org/10.3390/ijms23073620

Chicago/Turabian Style

Papadakos, Stavros P., Nikolaos Dedes, Alexandros Pergaris, Maria Gazouli, and Stamatios Theocharis. 2022. "Exosomes in the Treatment of Pancreatic Cancer: A Moonshot to PDAC Treatment?" International Journal of Molecular Sciences 23, no. 7: 3620. https://doi.org/10.3390/ijms23073620

APA Style

Papadakos, S. P., Dedes, N., Pergaris, A., Gazouli, M., & Theocharis, S. (2022). Exosomes in the Treatment of Pancreatic Cancer: A Moonshot to PDAC Treatment? International Journal of Molecular Sciences, 23(7), 3620. https://doi.org/10.3390/ijms23073620

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Menu

Exosomes in the Treatment of Pancreatic Cancer: A Moonshot to PDAC Treatment?

Abstract

Share and Cite

Article Metrics

Article Access Statistics

Further Information

Guidelines

MDPI Initiatives

Follow MDPI